RANKL/RANK/OPG: key therapeutic target in bone oncology. - Wikidata - awgldk - TriplyDB

RANKL/RANK/OPG: key therapeutic target in bone oncology.

RANKL/RANK/OPG: key therapeutic target in bone oncology.

http://www.wikidata.org/entity/Q37140665

about

Green tea and bone health: Evidence from laboratory studies.Primary bone tumors of the spine revisited: A 10-year single-center experience of the management and outcome in a neurosurgical department Osteoprotegerin Induces Apoptosis of Osteoclasts and Osteoclast Precursor Cells via the Fas/Fas Ligand Pathway Green tea and bone metabolism.Therapeutic implications of osteoprotegerin.RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization.Steroid hormone metabolizing enzymes in benign and malignant human bone tumors.Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer.RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.Vascular patterning and permeability in prostate cancer models with differing osteogenic properties.hRpn13, a newly identified component of the 19S particle, regulates proliferation, differentiation, and function in the human osteoblast-like cell line MG63. [corrected].hMSC-Derived VEGF Release Triggers the Chemoattraction of Alveolar Osteoblasts.Detection of rankl positive cells in gingival tissue in healthy & chronic periodontal disease patients-a comparative study Effect and mechanism of pyrroloquinoline quinone on anti-osteoporosis in Bmi-1 knockout mice-Anti-oxidant effect of pyrroloquinoline quinone.Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties.

P2860

Q35068737-56F57EE1-89AA-45D7-AEDB-765B5EC4495E Q35182876-E43FD6DD-73FB-46A0-A766-87383121FD6F Q35842259-148D04EC-EF7E-47D5-83C0-615AE703FBF9 Q37368071-BFC4BC3E-378D-4995-A708-466677347626 Q37368570-004EB134-9175-44AE-B69C-352EB3DCE3B5 Q37648868-4C383DD2-60A5-4B5C-82A8-91885C6A73DD Q37681557-5239767E-B898-4F47-A0E8-56C60D721CAF Q37803537-5A5DA659-696C-41B1-A354-A9D4DC71648A Q38331262-0F1C604F-1068-401F-943B-626AF3A43FDE Q38938475-58E75F4D-D6B1-449B-8C90-E1C09CA6E5D2 Q39434282-02EADAFB-9E55-4E68-B670-03F910B2D20E Q39447209-21E6D0E9-BA9E-441B-ABDA-14A5FAB678DB Q40667963-CCCCA182-00FC-47C3-8F03-2CE5CBD1870E Q42148430-3CCEDB87-74DB-4FA4-90E0-376125F63C1B Q47162342-7D56F74F-5F15-4578-906D-E74ADA9FA2BF Q54391573-E7F956C4-A095-4FA0-93A8-D024EF4A069F

P2860

RANKL/RANK/OPG: key therapeutic target in bone oncology.

http://www.wikidata.org/entity/Q37140665

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

RANKL/RANK/OPG: key therapeutic target in bone oncology.

@en

RANKL/RANK/OPG: key therapeutic target in bone oncology.

@nl

type

label

RANKL/RANK/OPG: key therapeutic target in bone oncology.

@en

RANKL/RANK/OPG: key therapeutic target in bone oncology.

@nl

prefLabel

RANKL/RANK/OPG: key therapeutic target in bone oncology.

@en

RANKL/RANK/OPG: key therapeutic target in bone oncology.

@nl

P1433

Q37140665-1547C148-1ED6-4584-B44D-57A2CA354A82

P1476

Q37140665-363EDDB4-3BE0-4FAA-80EC-FA64246B5A54

P2093

Q37140665-32F39A0E-84E8-4E9F-8BA1-4EB93D234616

Q37140665-57B7494C-789B-43F0-9695-B4F23475A2D7

Q37140665-8DAEE3A6-5190-42EA-B776-EBFA27394265

P2860

Q37140665-0B6BC154-E2AE-4D22-BA5A-231B4D498F5F

Q37140665-0C51FD39-39F1-4814-8812-928389E173C9

Q37140665-11DA412C-9985-41E8-9AA3-F607B6609491

Q37140665-121F3FF3-1D3C-4BEB-916B-9A18EBABFB68

Q37140665-12534F51-3FD3-4FC3-B2B9-E1CD28D22B4A

Q37140665-15D91C27-67F4-49BC-83CD-98EACEAC5E75

Q37140665-1861F4F1-1B66-4A74-99C4-A891F672F16B

Q37140665-1C55D489-6716-4B96-B84F-D11762554F03

Q37140665-1F172A17-E27C-43A9-90DA-CD2F9F6350F0

Q37140665-23EF4882-12A5-4DEF-AAE6-C0F555629C77

P304

Q37140665-FCFD5D6D-DB38-4A0A-A076-1482C8357911

P31

Q37140665-3F1F2328-73DC-4E02-AE71-FE21D00215D1

P356

Q37140665-1C10D64C-D767-4363-976D-B0765B316128

P433

Q37140665-D95A8D40-47BC-4B0B-946B-BC90FC0806F8

P478

Q37140665-7CF77260-0BDD-4F18-ABB3-98D4861CA5F0

P50

Q37140665-D99D089D-96D2-47F0-B71A-2A19022AC6C0

P577

Q37140665-A6D05FAD-184C-4DEC-946D-500847F37E8B

P698

Q37140665-CFDEAD75-D350-4221-9168-A7305363453D

P932

Q37140665-91B3B9E9-24D4-4509-ABC5-0442FA50AD98

P356

157016308785739857

P1433

Current Drug Discovery Technologies

P1476

RANKL/RANK/OPG: key therapeutic target in bone oncology.

@en

P2093

Francoise Rédini

http://www.w3.org/2001/XMLSchema#string

Kanji Mori

http://www.w3.org/2001/XMLSchema#string

Kosei Ando

http://www.w3.org/2001/XMLSchema#string

P2860

Human giant cell tumors of bone identification and characterization of cell types

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Bone versus immune system

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

P304

263-268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/157016308785739857

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Heymann

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18690894

http://www.w3.org/2001/XMLSchema#string

P932

2661019

http://www.w3.org/2001/XMLSchema#string